{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T05:27:37Z","timestamp":1730957257932,"version":"3.28.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ygyno.2024.08.009","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T04:28:06Z","timestamp":1724387286000},"page":"113-118","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Investigating the timing and site of recurrence for ovarian clear cell carcinoma: Analysis of the JGOG\/GCIG trial-JGOG 3017-A3"],"prefix":"10.1016","volume":"190","author":[{"given":"M.","family":"Yunokawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Kurihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Ishizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Kanao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Kajiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2024.08.009_bb0005","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1186\/s12885-019-6139-6","article-title":"Global patterns and trends in ovarian cancer incidence: age, period and birth cohort analysis","volume":"19","author":"Zhang","year":"2019","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.ygyno.2024.08.009_bb0010","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3322\/caac.21456","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"11","key":"10.1016\/j.ygyno.2024.08.009_bb0015","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1002\/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5","article-title":"Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy","volume":"88","author":"Sugiyama","year":"2000","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2024.08.009_bb0020","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ygyno.2019.03.243","article-title":"Trends and characteristics of epithelial ovarian cancer in Japan between 2002 and 2015: a JSGO-JSOG joint study","volume":"153","author":"Machida","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.08.009_bb0025","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","article-title":"Epithelial ovarian cancer","volume":"393","author":"Lheureux","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ygyno.2024.08.009_bb0030","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ygyno.2006.12.024","article-title":"Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary","volume":"105","author":"Crotzer","year":"2007","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2024.08.009_bb0035","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ygyno.2008.02.006","article-title":"Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers","volume":"109","author":"Chan","year":"2008","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2024.08.009_bb0040","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease\u2020","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann. Oncol."},{"issue":"24","key":"10.1016\/j.ygyno.2024.08.009_bb0045","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1200\/JCO.2016.66.9010","article-title":"Randomized phase III trial of irinotecan plus cisplatin compared with paclitaxel plus carboplatin as first-line chemotherapy for ovarian clear cell carcinoma: JGOG3017\/GCIG trial","volume":"34","author":"Sugiyama","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2024.08.009_bb0050","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2024.08.009_bb0055","unstructured":"National Comprehensive Cancer Network. Ovarian cancer including fallopian tube carcinoma and primary peritoneal cancer. In: NCCN Guidelines, Version 1.2022. Available at: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1453. [Accessed 08 May 2022]."},{"issue":"3","key":"10.1016\/j.ygyno.2024.08.009_bb0060","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s10147-016-0985-x","article-title":"Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of ovarian cancer including primary peritoneal cancer and fallopian tube cancer","volume":"21","author":"Komiyama","year":"2016","journal-title":"Int. J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2024.08.009_bb0065","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2021.32.e49","article-title":"The 2020 Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer","volume":"32","author":"Tokunaga","year":"2021","journal-title":"J. Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.08.009_bb0070","first-page":"143","article-title":"Platinum-based chemotherapy of high-risk stage I epithelial ovarian cancer following comprehensive surgical staging","volume":"82","author":"Rubin","year":"1993","journal-title":"Obstet. Gynecol."},{"issue":"3","key":"10.1016\/j.ygyno.2024.08.009_bb0075","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/PGP.0b013e3181c042b6","article-title":"Differences in tumor type in low-stage versus high-stage ovarian carcinomas","volume":"29","author":"K\u00f6bel","year":"2010","journal-title":"Int. J. Gynecol. Pathol."},{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2024.08.009_bb0080","doi-asserted-by":"crossref","first-page":"i50","DOI":"10.1093\/annonc\/mdw086","article-title":"Clear-cell carcinoma of the ovary","volume":"27","author":"Fujiwara","year":"2016","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2024.08.009_bb0085","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2018.29.e37","article-title":"Retrospective analysis of sites of recurrence in stage I epithelial ovarian cancer","volume":"29","author":"Hirose","year":"2018","journal-title":"J. Gynecol. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2024.08.009_bb0090","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1007\/s10147-020-01714-w","article-title":"Aggressive surgery for advanced ovarian cancer decreases the risk of intraperitoneal recurrence","volume":"25","author":"Tate","year":"2020","journal-title":"Int. J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.ygyno.2024.08.009_bb0095","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.ejca.2006.03.025","article-title":"Impact of pattern of recurrence on clinical outcome of ovarian cancer patients: clinical considerations","volume":"42","author":"Ferrandina","year":"2006","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"10.1016\/j.ygyno.2024.08.009_bb0100","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1136\/ijgc-2019-000287","article-title":"Patterns of recurrence and impact on survival in patients with clear cell ovarian carcinoma","volume":"29","author":"Hogen","year":"2019","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"9","key":"10.1016\/j.ygyno.2024.08.009_bb0105","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1097\/IGC.0000000000000270","article-title":"Patterns of recurrence and role of pelvic radiotherapy in ovarian clear cell adenocarcinoma","volume":"24","author":"Macrie","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"9747","key":"10.1016\/j.ygyno.2024.08.009_bb0110","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(10)61268-8","article-title":"Early versus delayed treatment of relapsed ovarian cancer (MRC OV05\/EORTC 55955): a randomised trial","volume":"376","author":"Rustin","year":"2010","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.ygyno.2024.08.009_bb0115","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","article-title":"Secondary surgical cytoreduction for recurrent ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.ygyno.2024.08.009_bb0120","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","article-title":"Randomized trial of cytoreductive surgery for relapsed ovarian cancer","volume":"385","author":"Harter","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ygyno.2024.08.009_bb0125","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1136\/ijgc-2018-000142","article-title":"Oncologic outcomes after secondary surgery in recurrent clear-cell carcinoma of the ovary","volume":"29","author":"Kajiyama","year":"2019","journal-title":"Int. J. Gynecol. Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824010631?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824010631?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T02:06:03Z","timestamp":1730945163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825824010631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":25,"alternative-id":["S0090825824010631"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.08.009","relation":{},"ISSN":["0090-8258"],"issn-type":[{"type":"print","value":"0090-8258"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigating the timing and site of recurrence for ovarian clear cell carcinoma: Analysis of the JGOG\/GCIG trial-JGOG 3017-A3","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}